News

CRUK's Annual Review 2017/18

Published: 04th September, 2018

Cancer Research UK have published their Annual Review for 2017/18 with a major focus on the Early Detection of Cancer. Pages 30-39 feature the chapter "Detecting and Diagnosing Cancer" which includes an article on Owlstone Medical and the PAN Cancer Trial that the company is running with the CRUK Cambridge Centre Early Detection Programme to detect cancer in breath samples.

The document also includes an interview with Sir Harpal Kumar, who stepped down as Chief Executive after more than 15 years with the charity. In his future vision he comments: “I hope it will include something in the area of early detection. We’re getting towards a breakthrough that’ll allow us to detect cancers at an early stage – including some of the most aggressive, dangerous ones – and that’s going to have a huge impact on survival.”

Please click here to open the report.

CRUK remove post-PhD time restrictions on applications for fellowships to ensure greater flexibility

Published: 29th August, 2018

From September 2018 Cancer Research UK is removing the post-PhD time restrictions on applications for response-mode fellowships to ensure greater flexibility and equality.

Owlstone Medical and Cancer Research UK Cambridge Centre Early Detection Programme initiate Pan-Cancer clinical trial to evaluate breath biopsy for early detection of disease

Published: 22nd August, 2018

Trial aims to identify breath biomarkers to improve the early detection and diagnosis of different cancer types.

Owlstone Medical, a diagnostics company developing a breathalyzer for disease, will run the PAN Cancer trial for Early Detection of Cancer in Breath. The large scale clinical study will evaluate the use of Owlstone Medical’s Breath Biopsy® platform for the early detection of multiple cancer types.

Mutations in blood identify individuals at high risk of developing leukaemia

Published: 01st August, 2018

New study reveals that it is possible to identify people at high risk of developing Acute Myeloid Leukaemia (AML) years before they became ill.

Rosetrees Trust Interdisciplinary Prize for early detection of renal cell carcinoma

Published: 30th July, 2018

Successful application to Rosetrees Trust Interdisciplinary Prize 2018 for non-invasive diagnostic test for renal cell cancers at point of care.

Poster prize awarded at ICSA 2018

Published: 16th July, 2018

The International Cell Senescence Association (ICSA) conference 2018 took place from July 8th-11th in Montreal, Canada and was attended by members of the Munoz-Espin lab. Estela Gonzalez-Gualda, PhD student in the lab, was awarded a poster prize at the conference. Many congratulations Estela.

More accurate detection of prostate cancer is on its way

Published: 03rd July, 2018

Mr Vincent Gnanapragasam and Professor Andrew Flewitt featured on the BBC Look East Evening News of 2 July 2018. They have both been working on new devices to improve accuracy in prostate cancer detection. The coverage shows both tools, the CamProbe and the FBAR which should be safer and more accurate than the current PSA test.

Sorex sensors raises £1.2million

Published: 06th June, 2018

Sorex Sensors, a spin-out from the University of Cambridge Department of Engineering has secured an initial round of investment from Cambridge Enterprise, Cambridge Angels and Cambridge Capital Group. The Film Bulk Acoustic Resonator (FBAR) technology has many applications including in cancer detection. One of these applications in prostate cancer detection was investigated by Professor Flewitt and his team with funding from a CRUK Cambridge Centre Early Detection Programme pump-priming award.

Artificial Intelligence could lead to transformation in early diagnosis of cancer

Published: 22nd May, 2018

In a speech by Teresa May the Government has pledged millions of pounds of funding to develop artificial intelligence able to transform outcomes through early diagnosis of cancer and chronic disease through the Industrial Strategy Grand Challenges.

Industry and charities will work with the NHS to develop algorithms that can use patient data and lifestyle information to warn GPs when a patient should be referred to an oncologist or another specialist. It is estimated that AI could help prevent 22,000 deaths from cancer each year by 2033, and give patients an additional five years of healthy, independent life by 2035.

Was anyone harmed by the recent breast cancer screening scandal?

Published: 21st May, 2018

Dr Stephen John, Senior Lecturer in Philosophy of Public Health, Cambridge University has written about the ethical issues surrounding the recent news that IT errors resulted in women not being invited to their final breast screening appointment. He asks: 'Was anyone harmed by the breast cancer screening scandal?' In this balanced analysis Stephen argues that it all depends which direction you look in - read here

Page 2 of 6. 54 Items Found.